Immunotherapy: A Review of Key Clinical Studies

June 3-7, 2016; Chicago, Illinois
David R. Gandara, MD; Daniel M. Geynisman, MD; Sara Hurvitz, MD, FACP; Elias Jabbour, MD; Shaji Kumar, MD; Brian Rini, MD, FACP; Tiffany A. Traina, MD; and Heather A. Wakelee, MD, provide an analysis of key presentations on cancer immunotherapy from the 2016 Clinical Oncology meeting in Chicago.
Format: Microsoft PowerPoint (.ppt)
File Size: 759 KB
Released: September 19, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Expert faculty share patient case examples from clinical practice that highlight the importance of biomarker testing for NSCLC, from Clinical Care Options (CCO)

Charles W. Flexner, MD Released: September 23, 2022

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Phase III CodeBreaK 200 study of sotorasib vs docetaxel in previously treated KRAS G12C-mutated advanced non-small-cell lung cancer, presented at ESMO 2022 as reported by Clinical Care Options (CCO)

Released: September 22, 2022

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings